The alkylating chemotherapeutic agent cyclophosphamide (CTX) has direct tumoricidal and immunomodulatory properties, including the induction of homeostatic proliferation of T cells...These effects extended to other lymphodepleting treatments, such as gemcitabine and radiation therapy...Furthermore, combined CTX and αPD-1+αCTLA-4 treatment demonstrated efficacy across additional preclinical tumor models, including colorectal cancer and triple negative breast cancer. Overall, these findings highlight that the combination of CTX and ICB represents a clinically relevant approach in the treatment of immunotherapy-refractory tumors.

These improvements were consistently observed in the histopathological and immunohistochemical evaluations. Owing to its antioxidant, anti-inflammatory, autophagy-promoting, and pyroptosis-modulating effects, febuxostat may show promise as a potential therapeutic option for reducing CP-related gonadal dysfunction in males.

P2, N=40, Not yet recruiting, Fred Hutchinson Cancer Center

Our results indicate that NACT can alter active DNA demethylation markers. Breast cancer patients with prolonged DFS had lower leukocyte 5-mdC and higher urinary 5-mdC levels before chemotherapy. Thus, assessing 5-mdC in these minimally invasive biospecimens may provide prognostic information for breast cancer patients undergoing NACT.

P=N/A, N=14, Enrolling by invitation, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting --> Enrolling by invitation

P1/2, N=16, Recruiting, Misty Shields | Not yet recruiting --> Recruiting | Initiation date: May 2026 --> Aug 2026

The patient received combination chemotherapy with gemcitabine, carboplatin, and bevacizumab, achieving a near-complete metabolic response. Immunohistochemistry plays a crucial role in identifying the primary tumor origin. Management requires a staged approach with emergency surgical intervention followed by multidisciplinary oncological treatment for optimal outcomes.

This retrospective study investigated the relationship between baseline SLC28A3 expression levels, quantified via reverse-transcriptase polymerase chain reaction (qRT-PCR), and the incidence of AIHA in a cohort of CLL patients receiving fludarabine and cyclophosphamide (FC) therapy. These findings suggest that diminished baseline SLC28A3 expression may correlate with an elevated risk of fludarabine-emergent AIHA in CLL patients. Further validation through larger, prospective cohorts is essential to confirm the predictive utility of SLC28A3 expression for optimizing fludarabine-based therapeutic strategies.

Scanning electron microscopy, immunofluorescence, Western Blot, and other molecular functional assays show that the ERRα/LDHA axis drives lactate accumulation, downregulates inflammasome-related proteins (NLRP3, caspase-1, GSDMD and GSDMD-N), thereby suppressing pyroptosis and promoting resistance to cisplatin, carboplatin, and paclitaxel in ovarian cancer cells. Created in BioRender. Ren, Y. (2025) https://BioRender.com/qeh0dw8.

P=N/A, N=338, Recruiting, University Hospital, Tours | Trial completion date: May 2024 --> Sep 2028 | Trial primary completion date: Feb 2024 --> Jul 2028

P2, N=20, Recruiting, Shanghai Changzheng Hospital

P1, N=22, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027